镥-177前列腺特异性膜抗原在既往接受卡巴他赛治疗的转移性去势抵抗性前列腺癌患者中的活性及结局决定因素:PACAP研究
这项回顾性研究纳入8个欧洲中心126例既往接受卡巴他赛后使用镥-177前列腺特异性膜抗原(Lu-PSMA)治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,中位随访12.0个月,中位影像学无进展生存期(rPFS)为4.4个月,44%患者前列腺特异性抗原(PSA)下降≥50%,但rPFS有限。
要点
- 既往卡巴他赛后使用Lu-PSMA的mCRPC患者中位rPFS为4.4个月,中位总生存期(OS)为8.9个月。
- 55例(44%)患者PSA下降≥50%,客观缓解率(ORR)为35%。
- 去势抵抗时间<12个月与更短rPFS相关(p=0.01),治疗中PSA下降≥50%者rPFS、TTPSA和OS更长(均p<0.0001)。
核心结论
- Lu-PSMA在卡巴他赛后真实世界场景中显示显著的PSA下降,但rPFS有限。
- 不良基线特征、基线正电子发射断层扫描参数和PSA应答质量可能有助于识别不太可能从Lu-PSMA获益的患者。
研究设计与样本
- 回顾性分析,纳入8个欧洲中心连续接受卡巴他赛后Lu-PSMA治疗的mCRPC患者,共126例。
- 干预为每6-8周给予Lu-PSMA,剂量6-7.6 GBq。
主要发现
- 126例患者中,68%为国际泌尿病理学会(ISUP)4-5级,21%有内脏转移,7%仅有淋巴结病变。
- 可检测的50例患者中11例(22%)存在DNA损伤修复(DDR)改变。
- 患者接受Lu-PSMA的中位周期数为3(四分位距2-4)。
- 中位随访12.0个月,中位rPFS为4.4个月(95%CI 3.2-5.4),中位TTPSA为3.5个月(95%CI 3.0-4.6),中位OS为8.9个月(95%CI 6.5-12.7)。
- ORR为35%,55例(44%)患者PSA下降≥50%。
关键数值与推荐
- 去势抵抗时间<12个月与更短rPFS相关(p=0.01)。
- ISUP 4-5级(p=0.08)及基线PET参数包括PSMA平均标准化摄取值(SUV)和最大SUV(分别为p=0.06和0.05)呈现类似趋势。
- 既往卡巴他赛持续时间或DDR状态不影响结局。
- 治疗中PSA下降≥50%的患者rPFS、TTPSA和OS更长(均p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 局限性包括回顾性数据收集和研究者评估的rPFS。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both cabazitaxel and lutetium-177 prostate-specific membrane antigen (Lu-PSMA) improve survival in metastatic castration-resistant prostate cancer (mCRPC) after an androgen receptor pathway inhibitor and docetaxel, but there are limited data regarding Lu-PSMA activity after cabazitaxel. OBJECTIVE: To assess the activity of Lu-PSMA and determinants of outcomes after cabazitaxel in mCRPC. DESIGN, SETTING, AND PARTICIPANTS: A retrospective analysis was conducted of consecutive mCRPC patients from eight European centers treated with Lu-PSMA after cabazitaxel. INTERVENTION: Lu-PSMA every 6-8 wk at a dose of 6-7.6 GBq. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was radiographic progression-free survival (rPFS). The secondary endpoints included time to prostate-specific antigen (PSA) progression (TTPSA), overall survival (OS), PSA decline, objective response rate (ORR), clinical benefit, and safety. RESULTS AND LIMITATIONS: Of 126 patients, 68% had International Society of Urological Pathology (ISUP) grade 4-5 disease, 21% had visceral metastases, and 7% had lymph node disease only. DNA damage repair (DDR) alterations were detected in 11/50 (22%) patients with available testing. Patients received a median number of 3 Lu-PSMA cycles (interquartile range 2-4). With a median follow-up of 12.0 mo, the median rPFS was 4.4 mo (95% confidence interval [CI] 3.2-5.4), TTPSA 3.5 mo (95% CI 3.0-4.6), and OS 8.9 mo (95% CI 6.5-12.7). The ORR was 35%, and 55 patients (44%) experienced a PSA decline of ≥50%. The time to castration resistance of <12 mo was associated with shorter rPFS (p = 0.01). A similar trend was observed for ISUP grade 4-5 (p = 0.08), and baseline positron-emission tomography parameters including PSMA mean standardized uptake value (SUV) and maximum SUV (respectively, p = 0.06 and 0.05). The duration of previous cabazitaxel or DDR status did not impact outcomes. Patients experiencing a PSA decline of ≥ 50% on therapy demonstrated longer rPFS, TTPSA, and OS (all p < 0.0001). Limitations include retrospective data collection and investigator-based rPFS assessment. CONCLUSIONS: Lu-PSMA demonstrated a substantial PSA decline but limited rPFS after cabazitaxel in a real-life setting. Adverse baseline characteristics, baseline positron-emission tomography parameters, and quality of PSA response may help identify patients less likely to benefit from Lu-PSMA. PATIENT SUMMARY: Lutetium-177 prostate-specific membrane antigen (Lu-PSMA) improved outcomes in patients with castration-resistant prostate cancer, but there are limited data about its activity after cabazitaxel, a chemotherapy that is also the standard of care in this setting. We conducted a study across eight European centers and showed substantial responses on Lu-PSMA after cabazitaxel, although activity was short lived in a heavily pretreated population. Our findings prompt for real-life evaluation of Lu-PSMA in earlier settings to define the best therapeutic sequence.
引用
- Flippot R, Telli T, Velev M, et al. Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study. Eur Urol Oncol. 2024. PMID: 38664139. doi:10.1016/j.euo.2024.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。